TaiMed Biologics

TaiMed Biologics

CD4-Targeted Antibody Platform From Long-Acting HIV Therapy to Precision Immune Therapeutics

A CD4-Targeting Antibody Platform — from Long-Acting HIV Therapy to Precision Immunotherapy



COMPANY

Disclaimer

- Except for historical information contained herein, the matters set forth in this presentation are forward looking statements that are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are not based on historical facts but rather on management's expectations regarding future growth, results of operations, performance, future capital and other expenditures, competitive advantages, business prospects and opportunities.
- Statements in this presentation about our future plans and intentions, results, level of activities, performance, goals or achievements or other future events constitute forward looking statements. Wherever possible, words such as "anticipate", "believe", "expect", "may", "could", "will", "potential", "intend", "estimate", "should", "plan", "predict", or the negative or other variations of statements reflect management's current beliefs and assumptions and are based on the information currently available to our management.
- Investors are cautioned not to place undue reliance on these forward-looking statements, which are made as of the date of this presentation, and we assume no obligation to update or revise any forward-looking statements.

COMPANY

Company Overview & Investment Highlights

Company Overview · Ticker 4147.TWO (TPEX)

01 Leader in $CD4^+$-targeted antibody platform

02 Differentiated assets across commercial, clinical & research

03 Fully integrated in-house cGMP manufacturing

04 Validated across clinical and commercial dimensions

05 Differentiated licensing opportunity across HIV & autoimmune

TaiMed Biologics

STRATEGY

An antibody platform built on three core value assets

Three core value assets — Products · Pipeline · Platform

THE FOUNDATION

Commercial Product

Trogarzo®

Commercial capability

FDA-approved in 2018 — Taiwan's first and the world's first HIV monoclonal antibody

Commercial cash flow

Standard of care for MDR HIV; stable revenue funding the pipeline

Scientific validation

Real-world data confirm CD4 targeting is safe and effective

GROWTH ENGINE

Near-Term Engine

TMB-365/380

Market positioning

Targeting the fastest-growing long-acting segment of the multi-billion-dollar HIV market

Product differentiation

All-antibody, zero DDI, potential for at-home subcutaneous self-injection

Development progress

Successful Phase 2a; advancing into Phase 2b

NEXT WAVE

Next-Generation Engine

CD4-ADC Platform

HIV cure

TMB-365 armed with a payload to precisely clear the latent reservoir

Autoimmune

Unlocking an unmet, hundred-billion-dollar market

Platform extension

One platform, multiple payloads, multiple licensing opportunities

TaiMed Biologics

PIPELINE

A diversified portfolio of first-in-class assets

Area	Drug	Indication	Stage	Unmet Need
HIV	**Trogarzo® (ibalizumab)**	Multi-drug-resistant HIV	Commercial (2018)	**First-in-Class**
HIV	**TMB-365/380 IV**	Long-acting Q2M maintenance	Phase 2b (LPI 2026/05)	**First-in-Class**
HIV	**TMB-365/380 SC**	Monthly subcutaneous self-injection	Phase 1b/2a (2027 planned)	**First-in-Class**
HIV	**TMB-HIV ADC**	Precision HIV therapy / cure	Preclinical	**First-in-Class**
Autoimmune	**TMB-IMMUNE ADC**	Multiple autoimmune diseases	Early development	**First-in-Class**

Rooted in CD4. Expanded across modalities.

TaiMed Biologics

01

The Scientific Foundation of the Platform

The CD4 Platform & Lead Asset

Why CD4 · TMB-365 engineering · TMB-365/380 dual-antibody regimen

TaiMed Biologics

MARKET

The market opportunity

Market opportunity — HIV + autoimmune > US$470B by 2033

HIV drugs (2033)

Stable growth · total market ~US$58B

Long-acting segment (20%): US$12B

Autoimmune drugs (2033)

Rapid growth · total market ~US$410B

CD4-driven segment (20%): US$80B

Total

$470B

Addressable

$92B



TaiMed Biologics

SCIENCE

Why CD4+ T Cell is the key target

Why CD4 matters — enabling treatment and cure strategies

1 Host target

A higher barrier to resistance with broad combination potential

2 Clinically validated

Proven safe and effective in humans through Trogarzo®

3 Reservoir-associated

$CD4^+$ cells are the latent reservoir → an entry point for cure

4 Internalization

Enables targeted payload delivery

5 Platform Application

Expandable to multiple $CD4^+$ T cell–driven diseases

TaiMed Biologics

SCIENCE

TMB-365: a clinically validated CD4 antibody

Engineered from ibalizumab · Humanized IgG1 · Post-attachment inhibitor

1

Enhanced breadth

N-glycan engineering yields broader HIV-1 coverage than ibalizumab

2

Extended half-life

FcRn and pH-dependent binding engineering support long-acting exposure

3

Clinical validation

Established safety profile; Phase 1/2 proof-of-concept completed

Pharmacokinetics (PK): overcoming the limits of conventional CD4 antibodies

- pH-dependent CD4 binding + FcRn recycling engineering → reduced target-mediated clearance and long-acting exposure
- Broader Broad antiviral coverage
- PK modeling supports dosing intervals extended to Q12W, fitting emerging long-acting HIV therapy

TaiMed Biologics

DATA

TMB-365 shows broad activity against multi-drug-resistant HIV

Broad activity across diverse and multi-drug-resistant HIV

98-100%

MPI across diverse HIV subtypes

Subtype	n	Ibalizumab %	TMB-365 %
A	3 panels	78–99	**99–100**
AE	3 panels	73–99	**98–100**
D	3 panels	84–96	**100**
B	1 isolate	76	**99**
C	2 isolates	78–80	**99**
AG	1 isolate	71	**99**

Broad antiviral coverage supports maintenance-therapy development.

TaiMed Biologics

LEAD ASSET

TMB-365/380: a dual-mechanism all-antibody HIV therapy

Dual mechanism of action — host target + viral target

TMB-365

Second-generation CD4 antibody

Role: Host-directed attachment inhibitor

Action: Binds the CD4 receptor to block the viral entry gateway without affecting cell function.

TMB-380

Broadly neutralizing antibody (bNAb)

Role: Virus-directed neutralizer

Action: Directly binds and neutralizes the virus (gp120), preventing infection of new cells.

An innovative "dual-mechanism, all-antibody" maintenance therapy

Targets both the host cell (TMB-365) and the virus itself (TMB-380), creating complementary dual entry blockade.

Strategic Advantages

Very high resistance barrier

A complementary "lock the door, defuse the bomb" design makes it hard for the virus to escape via simultaneous mutation.

No drug-drug interactions

As large proteins they bypass hepatic CYP450 metabolism, fitting elderly patients with comorbidities.

No INSTI side effects

A non-integrase regimen that avoids weight gain and metabolic side effects.

TaiMed Biologics

DATA

Phase 2a clinical proof-of-concept

CROI 2025 late-breaker — durable suppression, clean safety

94%
Week 24 viral load <50 copies/mL

0
Confirmed virologic failures (VF)

0
Grade ≥3 treatment-related AEs

0
Injection-site reactions (ISR)

Key findings

- 24-week maintenance therapy: a single IV infusion every 8 weeks (4800 mg each) sustained viral suppression with stable CD4
- Enrollment completed with no prior susceptibility screening — breadth and potency cover multi-drug-resistant strains
- No SAEs, no Grade 3/4 events, no acute infusion reactions; low resistance risk
- **Phase 2b enrolled its first patient in Dec 2025; primary efficacy data expected in H1 2027**

TaiMed Biologics

DATA

TMB-365 + TMB-380

PHASE 2b

CD4 Target + gp120 Target



Ongoing Phase 2b (Enrollment complete)

88
Participants
(2:1 randomized)

Q8W
IV Dosing

48
Weeks
Treatment

Virologically
Suppressed
Population

Enrolled without baseline susceptibility screening

TaiMed Biologics

02

Differentiation & Competitive Positioning

Differentiation & Commercial Fit

No screening · Zero DDI · Dosing sweet spot · TPP vs standard of care

TaiMed Biologics

Three differentiating advantages of TMB-365/380

Three commercial differentiators for broad, durable adoption

01

Dual target - host cell and virus

No screening

- Broad viral coverage
- Very low resistance risk
- Expands the treatable population

02

Avoids drug-drug interactions

Zero DDI

- Pure antibodies are not metabolized by CYP450
- Lowers switching risk and eases the switching burden for patients with comorbidities
- No small-molecule drug–associated toxicity

03

Dosing "sweet spot"

Dosing sweet spot

- Q2M IV fits existing clinic-visit cadence
- Potential for Q1M subcutaneous self-injection
- Low risk of treatment failure resulting in infection

EDGE

TaiMed Biologics

SYNERGY

A complementary strategy for partners' long-acting franchises

A complementary host-targeted mechanism for LA franchises

As a host-directed (CD4) mechanism, TMB-365 is orthogonal to all virus-directed antiretroviral classes and can form new long-acting combinations with integrase, capsid, and envelope inhibitors.

Integrase inhibitors (INSTI)	✓ Integrase + CD4
Capsid inhibitors (e.g., LEN)	✓ Capsid + CD4
Envelope inhibitors	✓ Envelope + CD4
Reservoir-targeting ADC	✓ Reservoir ADC

Why TMB-365 changes the game

Host-targeted

Acts independently of viral mutation pathways, with a distinct resistance profile

Orthogonal mechanism

Complementary to virus-directed therapies, with no cross-resistance

Portfolio diversification

Enables new long-acting combinations that counter concentrated resistance risk

TaiMed Biologics

03

The CD4-ADC Platform & Cure

The CD4-ADC Platform

Reservoir biology · Reveal & Reduce · Preclinical PoC · Autoimmune expansion

TaiMed Biologics

HIV Cure — The Industry's Holy Grail

Holy Grail

Functional cure has been the ultimate unmet goal in HIV for over four decades—the Holy Grail that leading pharmaceutical companies continue to pursue

Market potential in prevalence

40.8M	1.2M	9.2M
Global (2024)	US	Global Untreated

Researched Approaches	Limitation
Reveal & Reduce	Systemic toxicity
Gene editing	Delivery challenge
CAR-T	Complex and high-cost process
bNAb	Not effective

TaiMed Biologics

THE CHALLENGE

Why Is HIV Cure So Challenging — and Why TaiMed Holds the Key

Suppression ≠ Elimination.
ART suppresses HIV replication but cannot eradicate the integrated latent reservoir in CD4⁺ T cells—the central obstacle to an HIV cure.

1 Latent reservoir

Replication-competent HIV integrates into the genome of long-lived CD4⁺ T cells and enters a latent state, evading both immune surveillance and antiretroviral therapy.

2 Reservoir persistence

Long-lived memory CD4⁺ T cells and homeostatic proliferation enable the HIV reservoir to self-renew and persist for decades.

3 Rapid viral rebound

Even a minimal HIV reservoir can trigger viral rebound within weeks after ART is discontinued.

Anti-CD4 Targeting: A Potential Solution

An HIV cure requires targeting and eliminating reservoir cells—the foundation of TaiMed's CD4-targeted ADC platform.

TMB-365 ADC enables the delivery of diverse therapeutic payloads directly to HIV reservoir cells, achieving high intracellular concentrations.

TaiMed Biologics

ADC PLATFORM

TMB-365 ADC Enables Two Complementary HIV Reservoir Reduction Strategies

LRA Payload
(Latency-Reversing Agent)

Objective
Expose latent Reservoir cells

Mechanism
Induce HIV transcription

Payloads
Ex Romidepsin



TACK Payload
(Targeted Activator of Cell Kill)

Objective
Eliminate HIV-expressing cells

Mechanism
Trigger selective cell death

Payloads
NNRTIs with TACK activity

A single CD4-targeting platform enables targeted delivery of both reservoir-reactivating and reservoir-elimination payloads to support HIV functional cure

TaiMed Biologics

PRECLINICAL

CD4-ADC preclinical proof-of-concept

Preclinical proof-of-concept — four validated milestones

01 High target specificity

Binds and internalizes into CD4⁺ cells

02 Selective intracellular release

Selectively deliver payload to CD4⁺ cells

03 Effective drug release

Payload release reaches inside target cells

04 In-vitro antiviral activity

TMB-365-ADC antiviral activity confirmed

Presented at IDWeek 2025 · the world's first HIV-specific ADC, targeting IND within two years.

TaiMed Biologics

AUTOIMMUNE

Applying the CD4-ADC platform to autoimmune disease

Extending the platform to CD4-driven autoimmune diseases

Disorder	Dominant $CD4^+$ subset	2024 market
Rheumatoid arthritis (RA)	Th1 / Th17	**$32B**
Multiple sclerosis (MS)	Th1 / Th17	**$28B**
Crohn's disease	Th1 / Th17	**$14B**
Ulcerative colitis (UC)	Th17 / Th2	**$11B**
Psoriasis	Th1 / Th17	**$11B**
Systemic lupus erythematosus (SLE)	Th1 / Th17	**$3B**

The TMB-365-ADC solution

- Precisely targets CD4 cells and releases drug locally at the target
- Substantially improves efficacy while reducing systemic dose and toxicity
- Avoids the black-box risks of JAK/TNF inhibitors (infection, thrombosis)
- Positioned to become a next-generation immunotherapy modality

$80B CD4-driven autoimmune addressable market

TaiMed Biologics

COMPETITIVE ADVANTAGE

Multiple layers of competitive protection

Why TMB-365 is Difficult to Replicate



One Platform, Multiple Drug Candidates

TaiMed Biologics

04

Growth, Valuation & Collaboration

Growth, Valuation & Partnership

Gilead-style roadmap · Value inflection · Catalysts · Licensing entry points

TaiMed Biologics

ROADMAP

Three-stage growth: building a world-class pharma company

A staged growth roadmap, mirroring Gilead's value trajectory

TaiMed's strategic roadmap directly mirrors Gilead's proven three-stage valuation growth.

01 Foundational innovation

Gilead: Tenofovir → $4B (2001)

Trogarzo®

A first-in-class CD4-directed antibody validated the core platform and drug-approval capabilities.

Market entry complete

02 Strategic diversification

Gilead: single-tablet regimens → $40B (2007)

TMB-365/380

The first long-acting HIV antibody combination extends TaiMed into front-line treatment.

Next valuation driver

03 Platform-led

Gilead: HCV/oncology → peak $144B (2015)

CD4-ADC platform

HIV cure and autoimmune disease unlock substantial long-term growth potential.

Future upside

TaiMed Biologics

VALUATION

TMB-365/380 asset valuation inflection

Value inflection — a staged valuation trajectory



~$1.0B

Asset valuation today

~$2.3B

After positive Phase 2b data

$9-12B

After expected 2030 BLA approval

Peak sales potential estimated at $3–4B · the 2030 point shown reflects the midpoint (~$10.5B) of a $9–12B range.

TaiMed Biologics

CATALYSTS

Key clinical and commercial catalysts

Milestones & catalysts, 2025–2030



TaiMed Biologics

PARTNERSHIP

Licensing and partnership opportunities

From market expansion to early innovation — multiple entry points

COMMERCIAL

Trogarzo®

STATUS

Actively expanding into the Middle East, North Africa, and Asia, on a mature commercial foundation.

OPPORTUNITY

Open to regional commercial licensing in select emerging markets to maximize product value.

LATE-STAGE

TMB-365/380

STATUS

Interim data in late 2026–early 2027; full clinical data in 2027.

OPPORTUNITY

Entering the licensing stage — seeking global or regional licensing and co-development partners.

PLATFORM

CD4-ADC Platform

STATUS

Preclinical proof-of-concept complete; targeting IND within two years.

OPPORTUNITY

Diverse collaboration: indication co-development (e.g., autoimmune) and platform technology licensing.

TaiMed Biologics

TaiMed is transforming HIV care and pioneering the future of precision immunotherapy

Three strategic reasons to partner on the CD4 platform

1

De-risked CD4 platform

The successful launch of Trogarzo® has validated the CD4 target, regulatory capability, and commercial-scale manufacturing.

2

Near-term growth engine

TMB-365/380: all-antibody, long-acting, zero DDI, no screening, at-home self-injection — entering a multi-billion to hundred-billion-dollar HIV market.

3

Platform-driven upside

Extending from HIV maintenance to CD4-ADC (HIV cure, autoimmune) opens long-term valuation upside.